Atherosclerotic encephalopathy; ischemic cerebral stroke, dyscirculatory encephalopathy; peripheral blood circulation disorders caused by atherosclerosis, diabetes mellitus (including diabetic angiopathy), inflammation; trophic disorders in tissues associated with venous lesions or microcirculation disorders (post-thrombophlebitic syndrome, trophic ulcers, gangrene, frostbite); obliterating endarteritis; angioneuropathy (Raynaud’s disease); poor circulation of the eye (acute, subacute, chronic circulatory insufficiency in the retina and choroid); dysfunction of the inner ear vascular origin, accompanied by hearing loss.
Pentoxifillin-N composition and form of release
The active ingredient is pentoxifylline.
It is produced in the form of a solution (2%).
It is an agent that causes vasodilation. It is a methylxanthine derivative. Its action is associated with the inhibition of phosphodiesterase and the accumulation of cAMP in vascular smooth muscle cells, blood cells, and other organs and tissues. It inhibits the aggregation of erythrocytes, platelets, increases their flexibility, reduces the increased concentration of fibrinogen in the blood, enhances fibrinolysis, thus reducing blood viscosity, improving its rheological properties. It also causes unexpressed myotropic vasodilatation, reducing OPSS, has a positive inotropic effect (increases the force of contraction of the heart). As a result, microcirculation and oxygen supply to tissues are improved. Slightly improves coronary circulation.
Pentoxifillin-N is used:
- with atherosclerotic encephalopathy;
- with ischemic cerebral stroke;
- with discirculatory encephalopathy;
- in violation of peripheral blood circulation caused by diabetic angiopathy, atherosclerosis, inflammatory processes;
- with trophic disorders in tissues associated with venous damage;
- in violation of microcirculation (frostbite, trophic ulcers, post-thrombophlebitic syndrome, gangrene);
- with obliterating endarteritis;
- with angioneuropathy (Raynaud’s disease);
- in case of impaired blood circulation of the eye (circulatory failure in the retina, choroid);
- in case of dysfunction of the inner ear associated with vascular pathology.
- if you are allergic to pentoxifylline, other methylxanthines;
- with intolerance to excipients;
- with massive bleeding;
- with hemorrhages in the retina;
- with cerebral hemorrhage;
- with hemorrhagic diathesis;
- with acute myocardial infarction;
- with an ulcer of the stomach, intestines.
Not for use in pediatrics.
Application during pregnancy and lactation
Do not use during these periods.
Method of administration and dosage
Pentoxifillin-N is administered parenterally, preferably by intravenous infusion.
The standard dose is 100-600 mg in 100-500 ml of solvent (Ringer’s lactate solution, isotonic glucose or sodium chloride solution) 1-2 times a day at a rate of 100 mg / hour. The maximum is 1200 mg / day.
Symptoms: nausea, dizziness, tachycardia, falling blood pressure, fever, agitation, fever, hot flashes, areflexia, loss of consciousness, tonic-clonic convulsions, vomiting of coffee grounds (gastrointestinal bleeding).
Treatment: stop further systemic absorption by primary removal (gastric lavage, induction of vomiting), the use of sorbents.
- Neurological disorders: headache, anxiety, dizziness, anxiety, sleep disturbances, aseptic meningitis, convulsions, tremors, agitation, paresthesias, hallucinations.
- Dermatological disorders: allergic skin reactions, edema, hyperemia of the skin of the face and upper chest (hot flashes), increased fragility of nails, exanthema.
- Digestive disorders: flatulence, abdominal pain, diarrhea, nausea, anorexia, constipation, intestinal atony, cholestasis, cholecystitis, hepatitis, thirst, dry throat, feeling of pressure in the stomach.
- Perceptual disorders: blurred vision, lacrimation, scotoma, conjunctivitis, migraine, ear pain, retinal detachment, retinal hemorrhage.
- Cardiovascular disorders: tachycardia, peripheral edema, arrhythmia, cardialgia, angina pectoris, drop / increase in blood pressure, hemorrhages, shortness of breath.
- Hematological disorders: aplastic anemia, thrombocytopenia, thrombocytopenic purpura, leukopenia, hypofibrinogenemia, pancytopenia, bleeding of different localization.
- Immune disorders: anaphylactic / anaphylactoid reactions, bronchospasm, anaphylactic shock, angioedema, pruritus, urticaria, skin flushing, rashes, Lyell’s syndrome, Stevens-Johnson syndrome;
- Others: taste disturbances, malaise, salivation, soreness and enlargement of lymph nodes, laryngitis, increase / decrease in body weight, nasal congestion, fever, hypoglycemia, hyperthermic syndrome, sweating.
- Changes in laboratory parameters: increased activity of AsAT, ALT, LDH, ALP.
Storage conditions and periods
Store Pentoxifillin-N in its original manufacturing container. Optimal temperature conditions: up to +25 degrees Celsius. Best for 2.5 years after production (see the date on the packaging).